Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Redx Pharma reveals progress on cancer treatments as it reports full year results

Redx Pharma is confident on its 2017 outlook as it develops a pipeline of cancer treatments and restructures the business
Redx
RedX expects to achieve £4.2mln in cost savings in its restructuring

Redx Pharma Plc (LON:REDX) said its co-founder, Peter Jackson, and chairman, Frank Armstrong, are stepping down from the board as it reported its full year results.

The drug maker, which began trading on AIM in March 2015, said Jackson will resign at the end of the month while Armstrong has decided not to stand for re-election at the upcoming annual general meeting. 

The announcement came as Redx posted a loss before tax of £15.5mln in the year to 30 September, compared to £8.9mln a year earlier, as the group invested heavily in a pipeline of new products.

Watch: Redx Pharma to refocus on key assets

Its pipeline includes the development of its Porcupine RXC004 treatment for pancreatic, biliary and gastric cancer. 

The drug will enter it first in-human studies following a clinical trial application (CTA) submission in the second quarter.

Redx is also developing leukaemia treatment BTK RXC005 and plans to make an investigational new drug application and CTA towards the end of 2017.

"Redx has created a world-class capability in small molecule drug discovery in oncology and immunology," said chief executive Neil Murray.

"We have a strong research engine that continues to deliver an innovative pipeline, but we must now shift our focus towards developing our key portfolio assets, specifically our Porcupine and BTK programs for hard to treat diseases."

Redx ended the year with net cash of £5.8m, compared to £9.4mln the previous year. The company generated other operating income of £2.4mln, down from the prior year’s £2.6mln, which included fund grants from the Business, Energy and industrial Strategy.

The company said it looks forward to 2017 with confidence to future developments of the business as it transitions from a pre-clinical to a clinical stage and undergoes a restructuring.

As part of the restructuring, the company plans to cut jobs by 60% to 86 positions, which will help achieve cost savings of about £4.2mln. 

View full REDX profile View Profile

Redx Pharma Plc Timeline

CN Research
April 06 2017

Related Articles

shutterstock_139366595.jpg
January 25 2017
The company's update reveals a company in rude health
picture of drug research
February 20 2017
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.
viagra2.jpg
September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use